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Abstract
All immunoglobulin G molecules carry N-glycans, which modulate their biological activity. Changes in
N-glycosylation of IgG associate with various diseases and affect the activity of therapeutic antibodies
and intravenous immunoglobulins. We have developed a novel 96-well protein G monolithic plate and
used it to rapidly isolate IgG from plasma of 2298 individuals from three isolated human populations.
N-glycans were released by PNGase F, labeled with 2-aminobenzamide and analyzed by hydrophilic
interaction chromatography with fluorescence detection. The majority of the structural features of the
IgG glycome were consistent with previous studies, but sialylation was somewhat higher than reported
previously. Sialylation was particularly prominent in core fucosylated glycans containing two galactose
residues and bisecting GlcNAc where median sialylation level was nearly 80%. Very high variability
between individuals was observed, approximately three times higher than in the total plasma glycome.
For example, neutral IgG glycans without core fucose varied between 1.3 and 19%, a difference that
significantly affects the effector functions of natural antibodies, predisposing or protecting individuals
from particular diseases. Heritability of IgG glycans was generally between 30 and 50%. The
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individual's age was associated with a significant decrease in galactose and increase of bisecting
GlcNAc, whereas other functional elements of IgG glycosylation did not change much with age. Gender
was not an important predictor for any IgG glycan. An important observation is that competition
between glycosyltransferases, which occurs in vitro, did not appear to be relevant in vivo, indicating
that the final glycan structures are not a simple result of competing enzymatic activities, but a carefully
regulated outcome designed to meet the prevailing physiological needs.
Glycosylation is a widespread post-translational modification capable of producing significant structural
changes to proteins. Contrary to the core N-glycan structure, which is essential for multicellular life (1),
mutations in genes involved in modifications of glycan antennae are common and cause a large part of
individual phenotypic variations that exist in humans and other higher organisms. Glycosylation of
membrane receptors modulates adaptive properties of the cell membrane and affects communication
between the cell and its environment (2). Deregulation of glycosylation is associated with a wide range
of diseases, including cancer, diabetes, cardiovascular, congenital, immunological and infectious
disorders (3–5). Variations in glycosylation are of great physiological significance because it has been
demonstrated that changes in glycans significantly modulate the structure and function of polypeptide
parts of glycoproteins (6), and a prominent example for this type of regulation is the immunoglobulin G
(IgG).
Each heavy chain of IgG carries a single covalently attached bi-antennary N-glycan at the highly
conserved asparagine 297 residue in each of the C 2 domains of the Fc region of the molecule. The
attached oligosaccharides are structurally important for the stability of the antibody and its effector
functions (7). In addition, 15–20% of normal IgG molecules also bear complex bi-antennary
oligosaccharides attached to the variable regions of the light chain, heavy chain or both (8, 9).
Decreased galactosylation of IgG glycans in rheumatoid arthritis was reported over 25 years ago (10)
and numerous subsequent studies of IgG glycosylation revealed a number of important functional
consequences of structural alterations in IgG glycans. For example, the addition of sialic acids
dramatically changes the physiological role of IgGs by converting them from pro-inflammatory into
anti-inflammatory agents (11, 12). Another structural change to IgG glycans, the addition of fucose to
the glycan core, interferes with binding of IgG to FcγRIIIa and dampens its ability to destroy target
cells through antibody dependent cell-mediated cytotoxicity (ADCC)  (13, 14). Lack of core fucose
enhances the clinical efficacy of monoclonal antibodies, which exert their therapeutic effect by ADCC
mediated killing (15–17). However, despite the undisputed importance of glycosylation for the function
of IgGs, a large scale study that identifies the variability and heritability of IgG glycosylation in human
populations has not been attempted.
One of the major bottlenecks in large scale proteomics and glycomics studies is protein purification
from a large number of samples. Affinity chromatography and liquid chromatography have been widely
used, as they are versatile techniques for this purpose. A combination of affinity chromatography and
monolithic supports exhibits many advantageous properties when compared with conventional
particulate supports (18–22). Monoliths are continuous stationary phases cast in a single piece with
very large and highly interconnected pores (23). In comparison to particulate supports where molecules
are transferred by diffusion, the high porosity of monoliths allows convective mass transport. This
makes resolution and dynamic binding capacity practically independent of the flow rate (24–27). High
dynamic binding capacity for large molecules and high flow rates at a very low pressure drop enable
rapid processing of large volumes of complex biological mixtures (28). Polymethacrylate monoliths,
specifically poly(glycidyl methacrylate-co-ethylene dimethacrylate), possess all of the above mentioned
H
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Chemicals
Human Samples
characteristics of monolithic supports. In addition, they are also known for their good mechanical
strength, pH resistance, high surface area, high porosity, and simple attachment of ligands to the epoxy
groups (29). One of the most commonly used bioaffinity ligands for the isolation of IgG is protein G
(30–32). All four subclasses of human IgG strongly bind to protein G through their Fc fragments. Here
we present the development and application of a 96-well Protein G monolithic plate for high
throughput isolation of IgG and its application for the first large scale population study of the IgG
glycome.
EXPERIMENTAL PROCEDURES
Glycidyl methacrylate, ethylene dimethacrylate, cyclohexanol, and 1-dodecanol were
purchased from Sigma-Aldrich (St. Louis, MO). Photoinitiator was purchased from CIBA (Basel,
Switzerland) and Protein G from GE Healthcare (Uppsala, Sweden). Sodium acetate, sulfuric acid, and
hydrochloric acid (37%) were obtained from Merck (Darmstadt, Germany). All the buffers were filtered
through a 0.45 μm pore size filter composed of Sartolon polyamide (Sartorius, Goettingen, Germany).
The 96-well plates with frits, mean pore size 36 microns, were purchased from Chromacol (Welwyn
Garden City, United Kingdom).
Chemicals for buffer preparations (phosphate buffered saline (PBS), Tris, HCl, NaOH, formic acid,
ammonium bicarbonate, propan-2-ol) were purchased from Fisher Scientific (Pittsburgh, PA) and
Sigma-Aldrich. Chemicals for running the SDS-PAGE were purchased from Invitrogen (Carlsbad, CA).
Sodium bicarbonate, DL-dithiothreitol, iodoacetamide, ammonium persulfate, 2-aminobenzamide,
sodium cyanoborohydride, acetic acid, and dimethyl sulfoxide were from Sigma-Aldrich and ultra pure
water (Purite Fusion 40 water purification system, Purite Ltd., Thame, UK) were used throughout.
This study was based on samples from respondents who were residents of the Croatian
Adriatic islands Vis and Korčula or the Northern Scottish Orkney Islands and who were recruited
within a larger genetic epidemiology program that sought to investigate genetic variability and map
genes influencing common complex diseases and disease traits in genetically isolated populations (33,
34). The genetic-epidemiology program on the islands began in 2002, and continues today. The
sampling framework was based on the voting register in Croatia, which was used to send postal
invitations to all adult inhabitants (over 18 years of age); in Orkney subjects were volunteers from the
Orkney Complex Disease Study, again aged over 18 years.
The sample for this study consisted of 906 subjects from the Vis island (39.4%), 915 (39.8%) from
Korčula island and 477 from the Orkney islands (20.8%) totaling to 2298 individuals. The age range for
the entire sample was 18–100 years (median age 56, interquartile range 22 years). There were 894 men
(39.2%) and 1384 women in the sample (60.8%), for 20 people gender data were missing. Heritability
analysis was performed for the Vis Island sample only, because of a more extensive number of familial
links. The genealogical information was reconstructed based on the Church Parish records and
information provided by the subjects, and then checked against genetic data on allele sharing between
relatives as a quality control measure to exclude data errors. The sample contained a total of 809
genealogical relationships (including 205 parent-child, 123 sibling, and 481 other relationships). The
Korčula sample contained a much lower number of familial links and because of large standard errors
arising from rather shallow genealogical records, we did not calculate heritability estimates for the
Korčula island sample.
All of the members of the three sample groups were interviewed by one of the trained surveyors, based
on an extensive questionnaire (35). The questionnaire collected data on personal characteristics (name,
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Preparation of Protein G Monolithic Plates
Isolation of IgG
date, and place of birth, gender, marital status, education level and occupation), selected health-related
lifestyle variables (such as diet and smoking status), health complaints, drug intake and hospitalization
records. Blood was taken in epruvetes containing anticoagulant and immediately processed; plasma was
separated by centrifugation and stored at −70 °C. This study conformed to the ethical guidelines of the
1975 Declaration of Helsinki. All respondents signed an informed consent form before participating in
the study and the study was approved by the appropriate Ethics Board of the University of Zagreb
Medical School and by Research Ethics Committees in Orkney and Aberdeen.
The 96-well plates consisting of a polymethacrylate (poly(glycidyl
methacrylate-co-ethylene dimethacrylate)) monolithic stationary phase with protein G coupled to the
epoxy groups and casted inside each well was custom designed and prepared by BIA Separations
(Ljubljana, Slovenia). The basic monolith was synthesized by a free-radical polymerization of GMA and
a cross-linking agent, EDMA, in the presence of porogenic solvents, cyclohexanol and dodecanol (60
vol.% of the reaction mixture) as described by Tennikova et al. (36), but instead of thermally initiated
polymerization, UV polymerization was used. The preparation of the monolithic stationary phase is a
simple process and the polymerization mixture, which consists of monomers and porogens, is
polymerized by applying heat and UV light. In both types of polymerization, an important property of a
monolithic macroporous material is the pore size distribution. The photoinduced copolymerization of
150 μl of the mixtures of monomers, cross-linking agent, photoinitiator, and porogenic solvents was
performed at room temperature directly in each well of 96 plates. The mixture was irradiated with a
constant intensity from a 5 × 8 W mercury lamp using a wavelength of 312 nm (UVItec Ltd, Cambridge,
UK) with an exposure time of up to 180 min. Although the instrument does not enable active cooling,
the temperature did not exceed 30 °C thus effectively excluding thermal initiation. After the
polymerization was completed, each well of the 96-well plate was extensively washed with ethanol to
wash out the porogenic solvents and other soluble compounds. The average pore size was determined
by intrusive mercury porosimetry (PASCAL 440 porosimeter, Thermoquest Italia, Rodano, Italy). The
pore size distribution of the monoliths were around 700 nm, which is comparable to thermally
polymerized monoliths (37). The immobilization of protein G on the monoliths in the 96-well plate was
performed by flushing the monoliths with protein G solution prepared in a buffer solution of sodium
acetate. Afterward the monoliths were flushed with deionized water and the deactivation of the
remaining epoxy groups was performed with 0.5 M solution of sulfuric acid.
Before use, the monolithic plate was washed with 10 column volumes (CV) of ultra pure
water and then equilibrated with 10 CV of binding buffer (1X PBS, pH 7.4). Plasma samples (50 μl)
were diluted 10 × with the binding buffer and applied to the Protein G plate. The filtration of the
samples was completed in 5 min. The plate was then washed five times with 5 CV of binding buffer to
remove unbound proteins. IgG was released from the protein G monoliths using 5 CV of elution solvent
(0.1 M formic acid, pH 2.5). Eluates were collected in a 96-deep-well plate and immediately neutralized
to pH 7.0 with neutralization buffer (1 M ammonium bicarbonate) to maintain the IgG stability. After
each sample application, the monoliths were regenerated with the following buffers: 10 CV of 10 × PBS,
followed by 10 CV of 0.1 M formic acid and afterward 10 CV of 1 × PBS to re-equilibrate the monoliths.
Each step of the chromatographic procedure was done under vacuum (cca. 60 mmHg pressure
reduction while applying the samples, 500 mmHg during elution and washing steps) using a manual
set-up consisting of a multichannel pipet, a vacuum manifold (Beckman Coulter, Brea, CA) and a
vacuum pump (Pall Life Sciences, Ann Arbor, MI). If the plate was not used for a short period, it was
stored in 20% ethanol (v/v) at 4 °C.
After repeated use of the plate contaminants present in the sample sometimes did not completely elute
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Glycan Release and Labeling
Exoglycosidase Digestions of 2-AB Labeled IgG N-Glycans
Hydrophilic Interaction Chromatography
MS Analysis of Glycans
from the monolithic stationary phase. A specific cleaning protocol was developed that included washing
with 0.1 M NaOH to remove precipitated proteins and with 30% propan-2-ol to remove strongly bound
hydrophobic proteins or lipids. This procedure effectively removed all precipitates and did not
significantly diminish IgG binding capacity of the immobilized protein G.
The purity of the isolated IgG was verified by SDS-PAGE with NuPAGE Novex 4–12% Bis-Tris gels in
an Xcell SureLock Mini-Cell (Invitrogen) according to the manufacturer. Precision Plus Protein All Blue
Standards (BioRad, Hercules, CA) was used as the molecular weight marker. The gels were run at 180 V
for 45 min, stained with GelCode Blue (Pierce) and visualized by a VersaDoc Imaging System (BioRad).
Glycan release and labeling was performed as reported previously (38).
Plasma proteins were immobilized in a block of SDS-polyacrylamide gel and N-glycans were released by
digestion with recombinant N-glycosidase F (ProZyme, CA). This was done in a 96-well microtiter plate
to achieve the best throughput of sample preparation. After extraction, glycans were fluorescently
labeled with 2-aminobenzamide.
The following enzymes, all purchased from
ProZyme (San Leandro, CA), were used for digestions: Sialidase A™/NANase III (recombinant gene
from Arthrobacter ureafaciens, expressed in Escherichia coli), 5 mU; α(1–2,3,4,6)fucosidase (bovine
kidney), 1.25 mU; α(1–3,4)-fucosidase (almond meal), 1.6 mU; β(1–3,4)-galactosidase (bovine testis), 5
mU; β(1–4)-galactosidase (Streptococcus pneumoniae), 2 mU; β-N-acetylhexosaminidase/HEXase I
(recombinant gene from Streptococcus pneumoniae, expressed in E. coli), 40 mU; α(1–2,3,6)-
mannosidase (jack bean), 150 mU. Aliquots of the 2-AB labeled glycan pool were dried down and
digested in a mixture of enzymes, corresponding 1X concentrated manufacturers buffer and water in
total volume of 5 μl. After overnight incubation at 37 °C, enzymes were removed by filtration through
the AcroPrep 96 Filter Plates, 10K (Pall Corporation, MI, USA). Digested glycans were then separated
by HILIC-UPLC for comparison against an undigested equivalent.
Fluorescently labeled N-glycans were separated by ultra performance
liquid chromatography on a Waters Acquity UPLC instrument consisting of a quaternary solvent
manager, sample manager and a FLR fluorescence detector set with excitation and emission
wavelengths of 330 and 420 nm, respectively. The instrument was under the control of Empower 2
software, build 2145 (Waters, Milford, MA). Labeled N-glycans were separated on a Waters BEH Glycan
chromatography column, 100 × 2.1 mm i.d., 1.7 μm BEH particles, with 100 mM ammonium formate,
pH 4.4, as solvent A and acetonitrile as solvent B. Recently reported methods for UPLC profiling of
glycans (39, 40) were used as a starting point for the development of the separation method that used
linear gradient of 75–62% acetonitrile at flow rate of 0.4 ml/min in a 20 min analytical run. Samples
were maintained at 5 °C before injection, and the separation temperature was 60 °C. The system was
calibrated using an external standard of hydrolyzed and 2-AB labeled glucose oligomers from which the
retention times for the individual glycans were converted to glucose units. Data processing was
performed using an automatic processing method with a traditional integration algorithm after which
each chromatogram was manually corrected to maintain the same intervals of integration for all the
samples. The chromatograms obtained were all separated in the same manner into 24 peaks and the
amount of glycans in each peak was expressed as % of total integrated area.
Before MS analysis of each glycan peak, the 2-AB labeled IgG N-glycan pool was
fractionated by hydrophilic interaction high performance liquid chromatography (HILIC) on a 100 × 2.1
mm i.d., 1.7 μm BEH particles column using a linear gradient of 75–62% acetonitrile with 100 mM
ammonium formate, pH 4.4, as solvent A and acetonitrile as solvent B. UltiMate Dual Gradient LC
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Calculation of Derived Glycosylation Traits
system (Dionex, Sunnyvale, CA) controlled by Chromeleon software and connected to FP-2020 Plus
fluorescence detector (Jasco, Easton, MD) was used. To obtain the same separation as with UPLC
system, flow was adjusted to 0.3 ml/min and analytical run time was prolonged to 60 min. Collected
fractions were dried by vacuum centrifugation and resuspended in water.
Nano-LC-ESI-MS/MS. MS analysis of the collected glycan fractions was performed using an Ultimate
3000 nano-LC system (Dionex/LC Packings, Amsterdam, The Netherlands) equipped with a reverse
phase trap column (C  PepMap 100 , 5 μm, 300 μm × 5 mm; Dionex/LC Packings) and a nano
column (C  PepMap 100 , 3 μm, 75 μm × 150 mm; Dionex/LC Packings).
The column was equilibrated at room temperature with eluent A (0.1% formic acid in water) at a flow
rate of 300 nL/min. For fractions with disialylated glycans, extra 0.04% of trifluoroacetic acid was
added to the eluent A. After injection of the samples, a gradient was applied to 25% eluent B (95%
acetonitrile) in 15 min and to 70% eluent B at 25 min followed by an isocratic elution with 70% eluent
B for 5 min. The eluate was monitored by UV absorption at 214 nm. The LC system was coupled via an
online nanospray source to an Esquire HCTultra ESI-IT-MS (Bruker Daltonics, Bremen, Germany)
operated in the positive ion mode. For electrospray (1100–1250 V), stainless steel capillaries with an
inner diameter of 30 μm (Proxeon, Odense, Denmark) were used. The solvent was evaporated at 170 °C
employing a nitrogen stream of 7 L/min. Ions from m/z 500 to 1800 were registered. Automatic
fragment ion analysis was enabled, resulting in MS/MS spectra of the most abundant ions in the MS
spectra. Glycan structures were assigned using GlycoWorkbench (41).
MALDI-TOF-MS. 2-AB labeled glycan fractions were spotted onto an AnchorChip target plate (Bruker
Daltonics, Bremen, Germany). Subsequently 1 μl of 5 mg/ml 2,5-dihydroxybenzoic acid in 50%
acetonitrile was applied on top of each sample and allowed to dry at room temperature. MALDI-TOF-
MS was performed on an UltrafleX II mass spectrometer (Bruker Daltonics). Calibration was performed
on a peptide calibration standard. Spectra were acquired in reflector positive mode over the m/z range
from 700 to 3500 Da for a total of 2000 shots. Glycan structures were assigned using GlycoWorkbench
(41).
Derived glycosylation traits were approximated from the ratios of
glycan peaks (GP1-GP24) each of which combined the glycans with the same structural characteristics
(see Table I). The minor glycan peak GP3 was excluded from all the calculations because in some
samples it co-eluted with a contaminant that significantly affected its value. Derived traits were defined
as: the percentage of sialylation of fucosylated galactosylated structures without bisecting GlcNAc in
total IgG glycans-FGS/(FG + FGS) = SUM(GP16 + GP18 + GP23)/SUM(GP16 + GP18 + GP23 + GP8 +
GP9 + GP14)* 100; the percentage of sialylation of fucosylated galactosylated structures with bisecting
GlcNAc in total IgG glycans-FBGS/(FBG + FBGS) = SUM(GP19 + GP24)/SUM(GP19 + GP24 + GP10 +
GP11 + GP15)* 100; the percentage of sialylation of all fucosylated structures without bisecting GlcNAc
in total IgG glycans-FGS/(F + FG + FGS) = SUM(GP16 + GP18 + GP23)/SUM(GP16 + GP18 + GP23 +
GP4 + GP8 + GP9 + GP14)* 100; the percentage of sialylation of all fucosylated structures with
bisecting GlcNAc in total IgG glycans-FBGS/(FB + FBG + FBGS) = SUM(GP19 + GP24)/SUM(GP19 +
GP24 + GP6 + GP10 + GP11 + GP15)* 100; the percentage of monosialylation of fucosylated
monogalactosylated structures in total IgG glycans-FG1S1/(FG1 + FG1S1) = GP16/SUM(GP16 + GP8 +
GP9)* 100; the percentage of monosialylation of fucosylated digalactosylated structures in total IgG
glycans-FG2S1/(FG2+FG2S1+FG2S2) = GP18/SUM(GP18 + GP14 + GP23)* 100; the percentage of
disialylation of fucosylated digalactosylated structures in total IgG glycans-FG2S2/(FG2 + FG2S1 +
FG2S2) = GP23/SUM(GP23 + GP14 + GP18)* 100; the percentage of monosialylation of fucosylated
digalactosylated structures with bisecting GlcNAc in total IgG glycans-FBG2S1/(FBG2 + FBG2S1 +
18
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FBG2S2) = GP19/SUM(GP19 + GP15 + GP24)* 100; the percentage of disialylation of fucosylated
digalactosylated structures with bisecting GlcNAc in total IgG glycans-FBG2S2/(FBG2 + FBG2S1 +
FBG2S2) = GP24/SUM(GP24 + GP15 + GP19)* 100; ratio of all fucosylated (± bisecting GlcNAc)
monosialylated and disialylated structures in total IgG glycans-F S1/F S2 = SUM(GP16 + GP18 +
GP19)/SUM(GP23 + GP24); ratio of fucosylated (without bisecting GlcNAc) monosialylated and
disialylated structures in total IgG glycans-FS1/FS2 = SUM(GP16 + GP18)/GP23; ratio of fucosylated
(with bisecting GlcNAc) monosialylated and disialylated structures in total IgG glycans - FBS1/FBS2 =
GP19/GP24; ratio of all fucosylated sialylated structures with and without bisecting GlcNAc-
FBS /FS  = SUM(GP19 + GP24)/SUM(GP16 + GP18 + GP23); ratio of fucosylated monosialylated
structures with and without bisecting GlcNAc-FBS1/FS1 = GP19/SUM(GP16 + GP18); the incidence of
bisecting GlcNAc in all fucosylated monosialylated structures in total IgG glycans-FBS1/(FS1 + FBS1) =
GP19/SUM(GP16 + GP18 + GP19); ratio of fucosylated disialylated structures with and without
bisecting GlcNAc - FBS2/FS2 = GP24/GP23; the incidence of bisecting GlcNAc in all fucosylated
disialylated structures in total IgG glycans - FBS2/(FS2 + FBS2) = GP24/SUM(GP23 + GP24). The
following derived traits were approximated only from the ratios of glycan peaks containing neutral
glycan as a major structure. First, the percentage of each neutral glycan peak (GP1  - GP15 ) was
calculated from the total neutral glycan fraction (SUM(GP1:GP15)) and then traits were defined as: the
percentage of agalactosylated structures in total neutral glycan fraction-G0  = SUM(GP1  + GP2  +
GP4  + GP6 ); the percentage of monogalactosylated structures in total neutral glycan fraction - G1  =
SUM(GP7  + GP8  + GP9  + GP10  + GP11 ); the percentage of digalactosylated structures in total
neutral glycan fraction - G2  = SUM(GP12  + GP13  + GP14  + GP15 ); the percentage of all
fucosylated (±bisecting GlcNAc) structures in total neutral glycan fraction - F   = SUM(GP1  +
GP4  + GP6  + GP8  + GP9  + GP10  + GP11  + GP14  + GP15 ); the percentage of fucosylation of
agalactosylated structures-FG0  /G0  = SUM(GP1  + GP4  + GP6 )/G0  * 100; the percentage of
fucosylation of monogalactosylated structures-FG1  /G1  = SUM(GP8  + GP9  + GP10  +
GP11 )/G1  * 100; the percentage of fucosylation of digalactosylated structures-FG2  /G2  =
SUM(GP14  + GP15 )/G2  * 100; the percentage of fucosylated (without bisecting GlcNAc) structures
in total neutral glycan fraction-F  = SUM(GP1  + GP4  + GP8  + GP9  + GP14 ); the percentage of
fucosylation (without bisecting GlcNAc) of agalactosylated structures - FG0 /G0  = SUM(GP1  +
GP4 )/G0  * 100; the percentage of fucosylation (without bisecting GlcNAc) of monogalactosylated
structures -FG1 /G1  = SUM(GP8  + GP9 )/G1  * 100; the percentage of fucosylation (without
bisecting GlcNAc) of digalactosylated structures-FG2 /G2  = GP14 /G2  * 100; the percentage of
fucosylated (with bisecting GlcNAc) structures in total neutral glycan fraction-FB  = SUM(GP6  +
GP10  + GP11  + GP15 ); the percentage of fucosylation (with bisecting GlcNAc) of agalactosylated
structures-FBG0 /G0  = GP6 /G0  * 100; the percentage of fucosylation (with bisecting GlcNAc) of
monogalactosylated structures-FBG1 /G1  = SUM(GP10  + GP11 )/G1  * 100; the percentage of
fucosylation (with bisecting GlcNAc) of digalactosylated structures-FBG2 /GP2  = GP15 /G2  * 100;
ratio of fucosylated structures with and without bisecting GlcNAc-FB /F  = FB /F ; the incidence of
bisecting GlcNAc in all fucosylated structures in total neutral glycan fraction-FB /F   = FB /F
 * 100; ratio of fucosylated non-bisecting GlcNAc structures and all structures with bisecting
GlcNAc-F /(B  + FB ) = F /(GP13  + FB ); ratio of structures with bisecting GlcNAc and all
fucosylated structures (± bisecting GlcNAc)-B /(F  + FB ) (‰) = GP13 /(F + % FB ) * 1000; ratio of
fucosylated digalactosylated structures with and without bisecting GlcNAc-FBG2 /FG2  =
GP15 /GP14 ; the incidence of bisecting GlcNAc in all fucosylated digalactosylated structures in total
neutral glycan fraction-FBG2 /(FG2  + FBG2 ) = GP15 /(GP14  + GP15 ) × 100; ratio of fucosylated
digalactosylated nonbisecting GlcNAc structures and all digalactosylated structures with bisecting
GlcNAc-FG2 /(BG2  + FBG2 ) = GP14 /(GP13  + GP15 ); ratio of digalactosylated structures with
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Molecular Modeling
Statistical Analysis
Development of a New Affinity Material and Purification of IgG from 2298 Human Plasma Samples
Analysis of IgG Glycans
bisecting GlcNAc and all fucosylated digalactosylated structures (±bisecting GlcNAc)-BG2 /(FG2  +
FBG2 ) (‰) = GP13 /(GP14  + GP15 ) * 1000.
Overview of derived traits and glycans structures present in each chromatographic peak is available as
supplemental Table S1.
Molecular modeling was performed on a Silicon Graphics Fuel work station using
InsightII and Discover software (MSI Inc.). The crystal structure of IgG Fc (42) was used as the basis
for modeling (pdb code 1H3V; obtained from the Protein Data Bank (43). The IgG Fc used for
crystallization contains A2G2F glycans at Asn 297, but the majority of the 3-arm is disordered in the
crystal. Preferred conformations for the bisecting GlcNAc were obtained from the database of glycosidic
linkage conformations (44, 45).
The descriptive part of this study was based on non-parametric methods because
deviations from normal distribution were observed. Correlations were performed with Spearman's rank
test and gender differences were tested with the Mann-Whitney test. The basic analysis was performed
in genealogy unlinked individuals, in order not to bias the results with sample relatedness. The sample
size for the subset of these analyses was thus reduced to 612 samples from Vis Island (67.5% of the full
sample size), 520 samples (56.8%) from Korčula Island and 477 from Orkney islands, or 1609 samples
in total. SPSS version 13 was used in the analysis (SPSS Inc, Chicago, IL). In the last step of analysis we
used pedigree information and entire sample size to establish relationships between respondents to
calculate heritability estimates. Heritability analysis was conducted using polygenic models in
Sequential Oligogenic Linkage Analysis Routines (46). Age and sex were used as predictor variables in
these models. Significance was set at p < 0.05.
RESULTS AND DISCUSSION
The newly
developed protein G monolithic plate with the bed volume of a single protein G column of 150 μl was
used for IgG purification. Plasma samples (V = 50 μl) were diluted ten times with PBS, pH 7.4, and
loaded onto the columns. The dynamic binding capacity for IgG was not exceeded. The purity of eluted
fractions was examined by SDS-PAGE revealing two clearly visible bands corresponding to the
molecular masses of heavy ( 50 kDa) and light chains ( 25 kDa) of IgG (supplemental Fig. S1).
The newly developed 96-well protein G plates were used to purify IgG from 2298 plasma samples. The
entire chromatographic procedure for 96 samples, including the binding, washing and elution steps,
was performed in less than 30 min. The concentration of IgG in human plasma varies between 6.6 and
14.5 mg/ml (47). The average amount of IgG isolated from 50 μl of plasma with the use of 96-well
protein G monolithic plates was 640 μg, indicating that the majority of IgG in the sample was
successfully captured and released.
Because the elution of IgG from protein G requires very low pH, there is a certain risk of loss of sialic
acids because of acid hydrolysis. Isolation with monoliths minimized this risk as elution occurs within
seconds and therefore the pH was quickly restored to neutrality preserving the integrity and activity of
the IgG molecules. The use of a vacuum for liquid transfer enabled easy and efficient handling of large
sample sets.
N-glycans attached to IgG were released using PNGase F and labeled with 2-
aminobenzamide (2-AB). Labeled glycans were separated by hydrophilic interaction chromatography on
a recently introduced Waters BEH Glycan chromatography column. Because this was the first
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Galactosylation
application of this column for the analysis of IgG glycans in our laboratory, each chromatographic peak
was collected and analyzed by exoglycosidase digestion (data not shown) and mass spectrometry to
determine the glycan structures that elute in each peak (supplemental Table S2). A total of 23 major
and 10 minor glycan structures were successfully resolved (Fig. 1, Table I). An additional 40
glycosylation traits (galactosylation, core fucosylation, sialylation, etc.) were derived from ratios of these
glycan peaks as described in the Experimental Procedures section.
Approximately 96% of all neutral IgG glycans contained core fucose (Table II: F  ). In contrast with
immunoglobulins, which are mainly produced by B-cells, other major plasma glycoproteins generally
originate from hepatocytes, which express only very low levels of the FUT8 fucosyltransferase and thus
contain a low percentage of core fucosylated glycans (48). They are also generally more highly sialylated
and consequently over 35% of all glycans in human plasma are A2G2S2 structures (38). The median
level of A2G2S2 glycans in our IgG preparations was slightly over 3% (Table II: GP21), which is very
similar to previously reported values (49). This indicated that the level of contaminating plasma
proteins in our IgG preparations was very low, but because disialylated structures without core fucose
on IgG are of rather low frequency, even low level of contaminating plasma proteins would cause
significant errors in calculation of the sialylation level. To minimize this problem, all calculations of
sialylation-related traits were performed using only core fucosylated structures, which are predominant
on IgG and less abundant on other plasma proteins.
Galactosylation of IgG is one of the most studied glycosylation feature of any glycoprotein.
Because the discovery of decreased galactosylation of IgG in rheumatoid arthritis more than 25 years
ago (10), over 50 different studies have analyzed the role of IgG galactosylation in different
inflammatory diseases (50). In our three populations, neutral glycans without galactoses (G0 ) were
slightly below 40%, neutral glycans with one terminal galactose (G1 ) slightly above 40% and neutral
glycans with two terminal galactoses (G2 ) were 20% of the neutral IgG glycome (Table II). Because
only 11.6% of G1 was sialylated (Table II: FG1S1/(FG1+FG1S1)), whereas over 50% of G2 was sialylated
(Table II: FG2S2/(FG2+FG2S1+FG2S2) and FBG2S2/(FBG2+FBG2S1+FBG2S2)), in the total pool of
IgG glycans, median levels of a galactosylated, mono galactosylated, and digalactosylated structures-the
latter two with or without sialic acid-were approximately the same. However, the ratio of G0  to G2
increased significantly with age, (see section “Effects of Gender and Age”), thus the observed
equilibrium between glycans with different number of galactoses could be a peculiarity of our relatively
old study cohorts.
A clear preference for the addition of the first galactose to the antennae, which extend from the α1–6
linked mannose residues of the trimannosyl core (6-arm), was observed because over 65% of G1
structures contained galactose on the 6-arm (Table II: GP8/(GP8+GP9)). This difference was even
larger in structures containing bisecting GlcNAc where over 85% of all G1  structures contained
galactose on the 6-arm (Table II: GP10/(GP10+GP11)). This is in accordance with previous studies,
which demonstrated that on native IgG it is the 6-arm, which is preferentially galactosylated (51),
despite the fact that galactosyltransferase preferentially galactosylates the 3-arm of free biantennary
glycans in vitro (52). This apparent paradox results from the fact that glycans attached to Asn  of
IgG are located in a cleft between the two heavy chains (53), which affects their accessibility to
glycosyltransferases. Oligosaccharides and the polypeptide chains of the C 2 domain form multiple
noncovalent bonds (54). The majority of these interactions occur between the elongated antennae that
extend from the α1–6 linked mannose residues of the trimannosyl cores whereas the 3-arm extends
into the interstitial space between the C 2 domains and is therefore less accessible to
glycosyltransferases (42). Moreover, the addition of a galactose to the 3-arm does not directly affect the
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Sialylation
accessibility of the 6-arm allowing the G1 glycan to be converted to G2, whereas the addition of
galactose to the 6-arm reduces accessibility of the 3-arm and prevents further processing (55).
Sialylation of IgG recently attracted much attention after it was shown that it is responsible
for the anti-inflammatory activity of intravenously administered immunoglobulins (11, 56). IgG
antibodies have long been recognized as proinflammatory mediators of the humoral immune response.
Appropriate glycosylation of Asn  is essential for the proinflammatory activity of IgG antibodies by
maintaining the heavy chains in conformation, which favors binding to Fcγ receptors (57). Enzymatic
removal of this glycan significantly reduces FcγR binding and, consequently, the proinflammatory
activity in vivo (58). However, if the glycan is sialylated, the proinflammatory effect of IgG is reversed
and it now exerts anti-inflammatory effects (56), most probably through interactions with the lectin
receptor SIGN-R1 or DC-SIGN (12). This has significant implications for both the normal function of
IgG in the immune response and the application of intravenous immunoglobulins for the treatment of a
number of autoimmune diseases (59).
Approximately 10% of IgG glycans were found to terminate in sialic acid in a number of early studies
(57). We found that in our population the percentage of sialylated glycans was significantly higher with
median values being 20% in core fucosylated glycans without bisecting GlcNAc (Table II:
FGS/(F+FG+FGS)) and 29.5% in core fucosylated glycans with bisecting GlcNAc (Table II:
FBGS/(FB+FBG+FBGS)). The most probable cause for this apparent difference is the improvement in
methodology, which results in decreased hydrolysis of sialic acids during the purification of IgG and
glycan analysis. Both rapid elution and neutralization enabled by the use of newly developed protein G
monolithic plates, and the replacement of hydrazide (used in early studies) with PNGase F contributed
to the better preservation of sialic acid. However, it should be noted that some previous studies
analyzed only heavy chains of IgG, thus the Fab light chain glycans (which are generally more
sialylated) bound to light chains of IgG were excluded from the analysis. In addition, a recent
interlaboratory comparison of glycan analysis methods revealed that mass spectrometry routinely
underestimated sialic acid on IgG by nearly 3-fold, whereas HPLC analysis reported sialylation levels
very similar to the sialylation levels observed in our populations (60). However, this interlaboratory
comparison was performed on a small number of samples, and our study is the first large scale study to
reported such a high level of IgG sialylation. A more extensive international interlaboratory study of
glycan quantification concluded that permethylation of glycans can enable reliable quantification of
sialic acid on transferrin and IgG (61).
The variability of sialylation (of galactosylated glycans) in the population was also found to be rather
high, ranging from 17.6% to 47.5% in IgG without bisecting GlcNAc (Table II: FGS/(FG+FGS)), and
between 12.1% and 74.7% in IgG with bisecting GlcNAc (Table II: FBGS/(FBG+FBGS)). Because our
study participants came from a cross section study, it was not possible to clearly identify whether high
sialylation in some individuals was a genetic predisposition or a temporary physiological condition.
However, the extent of sialylation was found to be the most heritable element of IgG glycosylation (
Table III) indicating strong genetic regulation. This was further supported by relatively small changes in
sialylation observed in several individuals that were sampled a second time, after a period of 12
months (supplemental Fig. S2).
The majority of IgG glycans are attached to Asn  in the constant region of the heavy chain, but 15–
20% of IgG also contain glycans on the variable regions and some studies indicated that these glycans
are more sialylated, and particularly more bisialylated than Fc glycans (49, 62, 63). The most
comprehensive comparison of Fc and Fab IgG glycans was unfortunately performed on only two control
individuals and the difference of Fc sialylation in these two patients was rather large (49). However, in
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Fucosylation
Bisecting GlcNAc
Interactions Between Different Functional Elements of IgG Glycosylation
one of them over 70% of bigalactosylated glycans with both core fucose and bisecting GlcNAc were
sialylated, what is in line with our observations. Whether the observed variability of IgG sialylation
originates from Fab or Fc glycans is not known, but because individual differences in Fc sialylation
could have strong effects on the inflammatory response, this issue should be addressed in future
studies.
Core fucosylation of IgG has been intensively studied because of its role in ADCC. Natural
killer cells have receptors for the Fc domain of IgG. They bind to the Fc portion of IgG antibodies on
the surface of target cells, such as tumor cells, and release cytolytic components that kill the target cell.
This mechanism of killing is considered to be the major mechanism of antibody-based therapeutics
against tumors. Core fucose is very important in this process because IgG deficient in core fucose on
the Fc glycan was found to have ADCC activity enhanced by up to 100-fold (64). Endogenous serum
IgG inhibits therapeutic antibody-induced ADCC by competing for FcγRIIIa binding sites (17), but
nonfucosylated therapeutic IgG was reported to be able to evade this through higher affinity FcγRIIIa
binding (16). However, this might be highly dependent on the extent of core fucosylation of host IgGs.
In our populations the fraction of neutral IgG glycans without the core fucose was found to vary
between 1.3% and 19.3% (Table II; F  ) and this large variability could affect the efficacy of
therapeutic antibodies. Individuals with lower core fucose might need higher doses of the drug, thus the
extent of host IgG core fucosylation may need to be one of the parameters in the calculation of the
exact therapeutic dose.
The addition of bisecting GlcNAc to the IgG glycan by GlcNAc transferase III (GnTIII)
significantly affects its accessibility to other glycosyltransferases. For example, the addition of bisecting
GlcNAc prevents further branching because glycans with bisecting GlcNAc are not a substrate for GnTs
IV, V, and VI (65). Some studies also indicate that the presence of bisecting GlcNAc diminishes
galactosylation by GalT (66) and the addition of core fucose (67).
In our study, on average, 18% of neutral glycans contained bisecting GlcNAc (Table II: FB /F  ).
However, when the percentages of bisecting GlcNAc in G0 , G1 , and G2  structures were compared, a
significant decrease in the percentage of bisecting GlcNAc (nearly 50%) in G2  structures was observed
(Table II: FBG0 /G0 , FBG1 /G1 , and FBG2 /G2 ). At first sight, this seemed to confirm the results
of transfection assays, which indicated that GnTIII and GalT compete for an agalactosyl nonbisected
biantennary sugar chain as a common substrate (66). However, after considering this in the context of
not only neutral, but also sialylated glycans, the presence of a bisecting GlcNAc did not seem to have a
significant effect on IgG galactosylation. As presented in Table II and discussed in the “sialylation”
section, whereas only slightly below 10% of FA2G2 structures contained two sialic acids, over 40% of
FA2BG2 structures contained two sialic acids. Consequently, the decrease in bisecting GlcNAc in
neutral bigalactosylated structures (from 18% in mono galactosylated to 11% in digalactosylated) was
compensated by the increase in bisecting GlcNAc in bisialylated digalactosylated glycans (from 17% in
mono sialylated to over 55% in disialylated digalactosylated glycans). Therefore, the percentage of
digalactosylated structures with bisecting GlcNAc was approximately the same as for agalactosylated,
and monogalactosylated structures. The presence of bisecting GlcNAc apparently associated with the
increased addition of a second sialic acid, and consequently bisecting GlcNAc was underrepresented in
neutral digalactosylated and overrepresented in sialylated digalactosylated glycan pools.
Mutual interactions of the four above
described functional elements of IgG glycosylation have been addressed in the past, but different
experimental approaches (transfections, enzymatic assays, etc) often yielded conflicting results. Our
study is the first large-scale detailed analysis of IgG glycosylation in well-characterized human
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populations, which has therefore enabled reliable conclusions about the interrelation of different
functional elements. However, it is important to note that in vivo differences in the ratios of different
glycosylation elements in IgG may not simply reflect the kinetic characteristics of relevant
glycosyltransferases, but may result from regulatory elements, which govern IgG glycosylation and
modulate their glycans, presumably according to the prevailing functional needs of the host organism.
Only the most interesting associations are presented below, whereas the complete set of correlation
coefficients and their p values is available as supplemental material (supplemental Table S4).
Recently we reported the existence of a negative correlation between galactosylation and sialylation in
the human plasma glycome (68 + unpublished observations). A similar association was also found in
the IgG glycome where the percentage of bigalactosylated structures in the neutral IgG glycome strongly
negatively correlated with the percentage of disialylated glycans (r = –0.39, p = 7.3E-43; supplemental
Fig. S3). One interpretation of this observation is that sialylation might be a rate-limiting step and that
smaller amount of bigalactosylated structures can be more efficiently sialylated. The same observation
could also be a reflection of the simple fact that bigalactosylated glycan is a substrate for sialyl-
transferase and that efficient sialylation is decreasing the level of bigalactosylated glycans in the neutral
glycome by converting them into charged monosialylated and disialylated digalactosylated glycans.
However, in that case monosialylated glycans should also negatively correlate with the percentage of
digalactosylated glycans, what was not the case (supplemental Table S4).
Bisecting GlcNAc was reported to negatively affect both galactosylation (66) and fucosylation of IgG
(67). A moderate negative (r = –0.27), but statistically highly significant (p = 1.75E-20) correlation was
observed between bisecting GlcNAc (FB /F  total) and core fucosylation of IgG (F  total), which
confirmed the results from in vitro studies. However, in our study we did not observe any negative
correlation between the percentage of bisecting GlcNAc and galactosylation, indicating that in vivo
there is no competition between GnTIII and GalT. GnTIII, which adds bisecting GlcNAc, and GalT,
which adds galactoses clearly compete for the same substrate (66). The fact that this is not happening
in vivo is a very important observation because it demonstrates that final glycan structures are not a
simple result of competing enzymatic activities, but a predesigned outcome, presumably fitted to the
needs of the producing cells by some still unknown regulatory mechanisms. Confirmation of this
interpretation was provided by the comparison of Fab and Fc glycans in different myeloma lines, which
revealed strong site-specific regulation of glycosylation (69).
The most surprising observation was the large increase in the proportion of bisecting GlcNAc in
disialylated structures (FA2BG2S2, GP24), or alternatively the increase in sialylation of FA2BG2
glycans. Although 18% of all IgG Glycans (Table II: FB /F  ) contained bisecting GlcNAc, over
58% of all disialylated glycans contained bisecting GlcNAc (supplemental Table S3: FBS2/(FBS+FBS2).
Because FA2BG2S2 structure (GP24) represents only 2.7% of the total glycome, an additional check was
performed to confirm that this structure did not originate from contaminating plasma proteins. In the
total serum glycome, the ratio of A2G2S2 and FA2BG2S2 structures is 50:1 (70). Because the median
value of A2G2S2 (GP21) in our population was 3.3, even if all of it originated from contaminating
plasma proteins, the amount of FA2BG2S2 coming from the plasma proteins could be only up to
0.06%, which is far below the level that could significantly contribute to the observed increase in the
proportion of bisecting GlcNAc in disialylated IgG glycans.
Molecular modeling of IgG Fc with a bisecting GlcNAc on the Asn 297 glycan shows that the bisect can
be accommodated in a low energy linkage conformation with the rest of the glycan remaining in its
crystallographic position (i.e. with the 6-arm bound to the surface of the protein). However, the N-
acetyl group of the bisect is oriented close to the 6-arm GlcNAc and Phe 243 and may alter or disrupt
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Variability and Heritability of IgG Glycosylation
Effects of Gender and Age
the hydrophobic stacking between these two residues. This could result in the glycan 6-arm interacting
less strongly with the protein surface, making the entire glycan more mobile and both 3- and 6-arms
more likely to be available to glycosyltransferases.
In our recent analysis of the total plasma glycome in 915
individuals from the Croatian island of Vis we observed a median ratio of minimal to maximal values of
6.17 and significant age- and gender-specific differences (38). This study (which also includes the Vis
cohort) analyzed only the IgG glycome and revealed even higher variability in the population with
median ratio of minimal to maximal values of 17.2 for the whole IgG glycome and 19.7 for the neutral
IgG glycome. The variability of neutral glycans primarily originated from various percentage of
bisecting GlcNAc and core fucose on different neutral structures that represent a relatively small part of
the glycome, but even in some main glycosylation features the variability was rather high. For example
the proportion of G0 ranged between 14 and 70% and the proportion of G2 between 6 and 47% (
Table II). Bisecting GlcNAc and core fucose also varied significantly, but the most variable was the
sialylation of different glycan structures. The disialylated form of FA2G2 varied between 2.2 and 33% (
Table II: FG2S2/(FG2+FG2S1+FG2S2)), whereas the disialylated form of FA2BG2 varied between 16
and 60% (Table II: FBG2S2/(FBG2+FBG2S1+FBG2S2)).
Variations observed in a human phenotype are generally a combination of genetic differences and
environmental factors. Heritability is one of the most basic and often one of the first analyses to be
made in a genetic study, because it represents the proportion of the trait variance that can be attributed
to genetic factors, and it is often used as a screening tool to determine whether a trait may be suitable
for gene mapping (71). The fact that there are hundreds of genes involved in the complex glycan
metabolic pathways argues in favor of a strong genetic influence, but environmental effects on glycan
structures have also been reported (72–75). Recently we reported that there is a broad range of
variation in heritability levels of plasma glycans, from insignificant or very low to over 50% for some
glycans (38).
Using the large number of known genealogical relationships in our isolated populations we were able to
reliably estimate heritability of IgG glycans (Table III). Sialylation appeared to be the most
endogenously defined glycosylation feature, with up to 60% of variance explained by heritability. Age
had very little effect on the extent of sialylation, whereas gender was nearly irrelevant. Contrary to the
total plasma glycome, where gender played an important role in many glycans (68), gender was a
significant predictor in the IgG glycome, although only for some structures containing bisecting
GlcNAc. For the incidence of core fucose, bisecting GlcNAc and galactose, the heritability was generally
between 25 and 45%, indicating that a significant part of the variability of IgG glycosylation can be
explained by genetic polymorphisms.
A number of strong associations between IgG glycans and age were observed
and the most prominent ones are shown in Fig. 2. Individual's age was the most important predictor
for the level of IgG galactosylation, with 35% of variance of G0 explained by age (Table III). This
observation is in accordance with previous studies of galactosylation in aging (76, 77) and our recent
study of the total plasma glycome (68). The proportion of structures with bisecting GlcNAc also
increased with age, what is in accordance with the results of the recent large study of IgG glycans in
aging (77). However, contrary to the previous observations in plasma, the extent of core fucosylation of
IgG was not found to change with age (data not shown), indicating that the observed decrease in core
fucose with age in the total plasma glycome of women (68) could be the consequence of decreased IgG
concentration, and not alterations in the glycosylation metabolism in plasma cells. Another difference
between effects of age on glycosylation of IgG and total plasma proteins was observed in sialylation.
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Although in the total plasma glycome sialylation did not change with age (68), in IgG glycans there was
a significant decrease of sialylation of IgG with age (Fig. 2: FGS/(F + FG + FGS)). Very recently, the
logarithm of the ratio of fucosylated G0 to G2 structures (FA2/FA2G2), the so called GlycoAge index,
was suggested as a good indicator of individual's age (78). In our population this index was also a
reliable predictor of age with good separation of individuals in different decades of life (Fig. 3).
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Figures and Tables
Fig. 1.
UPLC analysis of the IgG glycome. IgG glycome was separated into 24 chromatographic peaks by hydrophilic
interaction chromatography. Compositions and structural schemes of glycans in each chromatographic peak and the
average percentage of individual structures are shown in Table I.
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Composition of the IgG glycome. IgG glycome was separated into 24 chromatographic
peaks by hydrophilic interaction chromatography. Structures of glycans in each
chromatographic peak and the average percentage of individual structures (%) were
determined by mass spectrometry. Structure abbreviations: all N-glycans have core sugar
sequence consisting of two N-acetylglucosamines (GlcNAc) and three mannose residues;
F indicates a core fucose α1–6 linked to the inner GlcNAc; Mx, number (×) of mannose on
core GlcNAcs; Ax, number of antenna (GlcNAc) on trimannosyl core; A2, biantennary
glycan with both GlcNAcs as β1–2 linked; B, bisecting GlcNAc linked β1–4 to β1–3
mannose; Gx, number of β1–4 linked galactose (G) on antenna; [3]G1 and [6]G1 indicates
that the galactose is on the antenna of the α1–3 or α1–6 mannose; Sx, number (×) of sialic
acids linked to galactose. Structural schemes are given in terms of N-acetylglucosamine
(square), mannose (circle), fucose (rhomb with a dot), galactose (rhomb) and sialic acid
(star)
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Table II
Descriptives of the IgG glycome in three populations. IgG glycans were analyzed for
individuals from the Croatian Adriatic islands Vis (n = 915), Korčula (n = 906) and
Orkney (n = 477). Median values, interquartile ranges (IQR), and minimal and maximal
values are shown. Calculations and descriptions of derived glycosylation traits are
explained in the Experimental Procedures section. An extended list of derived glycan
features is available in supplementary Table S3
IgG glycan
Population: Vis Population: Korčula Population: Orkney
Median
(IQR) Min-Max
Median
(IQR) Min-Max
Median
(IQR) Min-Max
GP1 0.16 (0.19) 0.02–2.38 0.15 (0.12) 0.03–1.02 0.16 (0.1) 0.04–1.24
GP2 0.74 (0.55) 0.11–5.2 0.72 (0.57) 0.14–9.39 0.71 (0.53) 0.17–4.59
GP4 20.39 (8.61) 6.56–42.37 20.05 (8.54) 6.07–41.34 20.14 (8.17) 8.08–49.47
GP5 0.31 (0.13) 0.09–0.97 0.29 (0.14) 0.12–0.97 0.27 (0.09) 0.13–0.84
GP6 5.24 (2.15) 1.93–12.86 5.5 (2.2) 1.79–11.09 4.82 (2.11) 1.95–10.65
GP7 0.67 (0.52) 0.14–4.01 0.68 (0.46) 0.15–4.06 0.48 (0.31) 0.12–1.72
GP8 16.42 (2.61) 9.84–23.7 16.2 (2.53) 8.93–23.56 18.08 (2.21) 11.89–25.4
GP9 7.9 (1.57) 4.27–11.8 7.95 (1.69) 4.6–12.19 8.98 (1.59) 5.01–12.5
GP10 4.59 (1.3) 2.48–10.2 4.6 (1.22) 2.59–8.19 4.48 (1.11) 2.64–13.37
GP11 0.75 (0.2) 0.33–2.92 0.76 (0.2) 0.4–1.82 0.77 (0.19) 0.44–1.41
GP12 0.96 (0.64) 0.26–6.14 0.98 (0.69) 0.23–3.91 0.8 (0.5) 0.21–3.87
GP13 0.25 (0.16) 0.08–1.59 0.22 (0.07) 0.1–1.01 0.24 (0.07) 0.13–0.58
GP14 11.02 (5.06) 3.39–22.97 10.77 (4.83) 3.5–24.81 12.26 (5.07) 3.66–23.91
GP15 1.41 (0.48) 0.71–2.89 1.51 (0.46) 0.68–2.81 1.64 (0.45) 0.77–2.83
GP16 3.13 (0.68) 1.99–5.11 3.21 (0.61) 1.82–5.22 3.21 (0.61) 1.69–5.25
GP17 2.61 (1.85) 1–13.61 2.43 (1.67) 0.94–10.45 1.58 (0.53) 0.92–7.73
GP18 8.58 (3.65) 3.96–18.02 8.83 (3.52) 3.58–26.02 9.33 (3.67) 3.45–18.92
GP19 2.45 (0.7) 1.16–9.03 2.41 (0.63) 1.15–5.1 2.38 (0.48) 1.3–4.54
GP20 0.43 (0.43) 0.07–3.25 0.62 (0.49) 0.11–3.46 0.49 (0.22) 0.25–2.56
GP21 3.41 (2.38) 1.03–23.82 3.2 (2.83) 0.98–24.6 1.56 (0.68) 0.67–6.01
GP22 0.36 (0.21) 0.06–1.33 0.31 (0.13) 0.08–1.46 0.29 (0.12) 0.06–0.88
GP23 1.98 (0.79) 0.71–13.73 2.27 (0.83) 0.9–4.67 2.3 (0.89) 0.88–4.62
GP24 2.7 (0.79) 1.02–7.66 2.72 (0.78) 0.67–5.84 2.66 (0.71) 0.97–8.86
FGS/(FG+FGS) 28.15 (4.52) 17.59–
47.45
29.5 (4.54) 19.02–42.8 27.32 (4.09) 19.63–
37.27
FBGS/(FBG+FBGS) 43.14 (8.86) 14.07–
74.67
43.05 (7.84) 21.95–
60.72
41.96 (7.16) 12.06–
66.91
FGS/(F+FG+FGS) 19.71 (6.03) 9.67–42.34 20.82 (5.82) 9.63–39.62 19.99 (5.39) 9.14–32.28
FBGS/(FB+FBG+FBGS) 29.91 (7.99) 10.16–
65.45
29.38 (7.64) 14.17–
48.83
29.70 (7.36) 10.37–51.19
FG1S1/(FG1+FG1S1) 11.49 (2.59) 7.38–22.13 11.79 (2.33) 7.21–22.05 10.67 (2.02) 5.99–15.84
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FG2S1/(FG2+FG2S1+FG2S2) 39.99 (3.28) 32.05–
49.45
40.72 (3.22) 33.24–
50.07
39.16 (3.26) 25.21–
48.48
FG2S2/(FG2+FG2S1+FG2S2) 8.99 (3.3) 3.61–33.21 10.08 (3.44) 2.18–30.64 9.45 (2.79) 4.18–20.31
FBG2S1/(FBG2+FBG2S1+FBG2S2) 37.2 (4.73) 26.27–
49.34
36.2 (4.66) 25.86–
46.49
35.92 (4) 26.32–
44.75
FBG2S2/(FBG2+FBG2S1+FBG2S2) 41.09 (5.92) 23.09–
59.58
40.73 (5.77) 15.88–
54.25
39.48 (4.59) 18.91–
62.28
FBS1/(FS1+FBS1) 0.17 (0.05) 0.08–0.52 0.17 (0.05) 0.04–0.36 0.16 (0.05) 0.07–0.31
FBS2/(FS2+FBS2) 0.58 (0.08) 0.36–0.75 0.55 (0.08) 0.37–0.78 0.54 (0.08) 0.32–0.78
G0 37.09 (12.75) 14.69–
69.57
37.22 (11.66) 13.84–
62.82
34.62 (11.46) 16.17–69.42
G1 42.6 (4.54) 24.18–
50.96
42.73 (4.38) 29.59–
49.26
44.45 (3.78) 24.73–
60.27
G2 19.17 (8.83) 5.93–43.76 18.88 (8.24) 7.05–47.09 20 (8.47) 5.64–40.27
F 95.77 (2.32) 84.19–
98.64
95.76 (2.37) 80.7–98.64 96.52 (1.8) 88.16–
98.67
FG0 /G0 97.11 (1.95) 81.33–
99.59
97.26 (2.09) 77.55–
99.52
97.15 (1.89) 86.42–
99.41
FG1 /G1 97.78 (1.67) 87.05–
99.57
97.76 (1.57) 86.77–
99.54
98.52 (0.91) 94.55–99.6
FG2  /G2 91.03 (5.05) 72.7–97.35 90.88 (4.32) 73.66–
98.08
92.95 (3.37) 80.66–
97.51
F 78.3 (4.62) 63.83–
87.48
77.99 (4.72) 60.95–
86.52
80.44 (4.05) 67.55–
88.92
FG0 /G0 77.02 (5.22) 49.91–
86.55
76.18 (5.93) 53.13–
86.54
78.3 (5.24) 59.25–
88.33
FG1 /G1 79.5 (4.5) 66.38–
87.63
79.68 (4.46) 67.99–
87.69
82.28 (4.1) 68.72–90.2
FG2 /G2 80.42 (5.74) 57.71–90.2 79.48 (5.58) 60.13–
89.57
81.59 (5.28) 63.28–
90.49
FB 16.92 (3.45) 10.87–25.9 17.27 (3.61) 10.49–
26.43
15.74 (3.37) 9–26.36
FBG0 /G0 19.85 (4.57) 12.16–33.2 20.64 (4.7) 11.66–
36.83
18.74 (4.14) 10.51–
32.08
FBG1 /G1 17.78 (3.91) 11.1–28.42 17.74 (4) 10.73–
28.46
16.17 (4.07) 8.85–30.76
FBG2 /G2 10.27 (2.39) 6.36–30.92 11.13 (3.06) 5.78–24.33 10.95 (3.06) 5.72–20.94
FB /F 17.76 (3.72) 11.05–
27.64
18.18 (3.94) 10.85–
27.81
16.35 (3.51) 9.23–26.91
Table III
Heritability of the IgG glycome. Heritability of individual glycans in the population of the
Croatian Adriatic island Vis was estimated using polygenic models in Sequential
Oligogenic Linkage Analysis Routines (SOLAR)
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IgG glycan
Covariates significance
H2 P (H2) S.E. (H2) Gender Age R
GP1 26.8% 0.010 0.117 0.771 2.00E-02 0.7%
GP2 26.1% 0.023 0.134 0.411 6.63E-24 11.1%
GP4 16.9% 0.061 0.114 0.128 2.52E-81 33.7%
GP5 0.0% 0.500 - 0.001 5.66E-01 1.3%
GP6 32.8% 0.001 0.113 0.218 4.68E-66 28.0%
GP7 13.0% 0.128 0.118 0.017 2.14E-01 0.7%
GP8 29.7% 0.005 0.116 0.271 2.60E-10 4.7%
GP9 29.1% 0.009 0.127 0.007 2.36E-01 1.0%
GP10 43.3% 0.000 0.118 0.037 2.18E-01 0.5%
GP11 17.0% 0.080 0.126 0.009 1.12E-14 7.2%
GP12 10.9% 0.170 0.118 0.049 3.65E-12 5.6%
GP13 1.5% 0.445 0.108 0.383 3.30E-02 0.6%
GP14 44.5% 0.000 0.112 0.040 4.85E-72 30.5%
GP15 36.2% 0.007 0.113 0.001 1.62E-30 14.9%
GP16 29.8% 0.008 0.127 0.074 7.30E-02 0.7%
GP17 27.9% 0.003 0.105 0.005 7.50E-02 1.2%
GP18 47.8% 0.000 0.112 0.329 7.86E-61 26.3%
GP19 40.3% 0.000 0.123 0.000 6.00E-02 2.2%
GP20 0.0% 0.500 - 0.001 8.46E-01 1.3%
GP21 19.3% 0.055 0.124 0.004 8.90E-03 1.8%
GP22 0.0% 0.500 - 0.309 6.12E-01 0.1%
GP23 17.9% 0.063 0.121 0.996 3.03E-11 4.8%
GP24 46.0% 0.000 0.113 0.008 1.22E-01 1.1%
FGS/(FG+FGS) 19.8% 0.052 0.126 0.099 7.74E-09 4.0%
FBGS/(FBG+FBGS) 39.7% 0.002 0.131 0.079 5.00E-03 1.4%
FGS/(F+FG+FGS) 21.7% 0.027 0.117 0.503 5.14E-58 25.4%
FBGS/(FB+FBG+FBGS) 11.5% 0.183 0.129 0.376 1.17E-07 3.2%
FG1S1/(FG1+FG1S1) 14.4% 0.118 0.123 0.740 1.75E-06 2.5%
FG2S1/(FG2+FG2S1+FG2S2) 40.2% 0.002 0.134 0.107 2.29E-02 0.8%
FG2S2/(FG2+FG2S1+FG2S2) 42.4% 0.000 0.121 0.443 2.03E-23 10.4%
FBG2S1/(FBG2+FBG2S1+FBG2S2) 47.9% 0.000 0.129 0.022 4.24E-19 9.3%
FBG2S2/(FBG2+FBG2S1+FBG2S2) 61.3% 0.000 0.110 0.810 2.30E-11 4.9%
FBS1/(FS1+FBS1) 56.4% 0.000 0.119 0.000 1.31E-47 22.1%
FBS2/(FS2+FBS2) 42.5% 0.000 0.122 0.000 5.64E-28 13.9%
G0 35.0% 0.001 0.118 0.779 2.96E-88 35.7%
G1 26.7% 0.014 0.124 0.948 7.74E-29 13.1%
G2 42.0% 0.000 0.109 0.009 1.02E-70 30.2%
F 37.0% 0.001 0.118 0.595 2.00E-01 0.1%
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FG0 /G0 47.2% 0.000 0.115 0.530 8.19E-01 0.1%
FG1 /G1 32.0% 0.004 0.123 0.726 4.39E-01 0.1%
FG2  /G2 29.6% 0.005 0.116 0.814 1.93E-07 3.2%
F 45.4% 0.000 0.115 0.129 9.00E-05 2.3%
FG0 /G0 45.4% 0.001 0.115 0.162 2.15E-01 0.3%
FG1 /G1 43.1% 0.000 0.124 0.006 3.00E-04 2.8%
FG2 /G2 13.6% 0.122 0.120 0.268 2.76E-23 10.7%
FB 33.3% 0.002 0.118 0.001 6.44E-18 8.8%
FBG0 /G0 29.8% 0.008 0.126 0.000 3.15E-01 1.6%
FBG1 /G1 32.5% 0.003 0.124 0.000 1.25E-07 4.7%
FBG2 /G2 47.3% 0.000 0.123 0.001 1.83E-01 1.3%
FB /F 29.6% 0.006 0.120 0.000 1.84E-16 8.4%
 Percent of variance explained in the model.
Fig. 2.
Association of IgG glycosylation with age. Distribution of G0  glycans, G2  glycans, the percent of structures with
sialic acid (FGS/(F+FG+FGS)) and bisecting GlcNAc (FB /F ) in fucosylated glycans between different age-groups
are shown. Central box represents the values from the lower to upper quartile (25 to 75 percentile). The middle line
represents the median. The horizontal line extends from the minimum to the maximum value, excluding “outside” and
“far out” values that are displayed as separate points.
Fig. 3.
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The Glyco-Age index. Glyco-Age index calculated as the logarithm of the ratio of fucosylated G2 and G0 structures
(FA2/FA2G2) was recently suggested to be a good indicator of individual's age (78). Median values of the Glyco-Age
index (with 95% confidence intervals as error bars) in our study population are shown.
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